Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 14

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 14
---
 the United States and other jurisdictions; |

| ● | our potential and ability                                                                                                              
 to successfully manufacture and supply CER-1236 and any other product candidates we may develop for clinical trials and for commercial 
 use, if approved;                                                                                                                      |

| ● | the rate and degree of                                                                                                              
 market acceptance of CER-1236 and any other product candidates we may develop, as well as the pricing and reimbursement of CER-1236 
 and any other product candidates we may develop, if approved;                                                                       |

| ● | our expectations regarding                                                                                                              
 our ability to obtain, maintain, protect and enforce intellectual property protection for CER-1236 and for any other product candidate; |

| ● | our ability to operate                                                                                                      
 our business without infringing, misappropriating or otherwise violating the intellectual property rights of third parties; |

| ● | our ability to realize                                  
 the anticipated benefits of any strategic transactions; |

| ● | our ability to attract                                                                                                              
 and retain the continued service of our key personnel and to identify, hire, and then retain additional qualified personnel and our 
 ability to attract additional collaborators with development, regulatory and commercialization expertise;                           |

| ● | our ability to maintain                 
 proper and effective internal controls; |

| ● | the ability to obtain or                                                                                              
 maintain the listing of our Common Stock, and our Public Warrants on the Nasdaq Stock Market LLC (“Nasdaq”) following 
 the Business Combination;                                                                                             |

| ● | the impact of macroeconomic                                         
 conditions and geopolitical turmoil on our business and operations; |

| ● | our expectations regarding                                                                                                       
 the period during which we will qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the 
 “JOBS Act”) and as a smaller reporting company under the federal securities laws; and                                            |

| ● | our anticipated use of                                         
 our existing cash, cash equivalents and marketable securities. |

We have based these forward-looking
statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends
that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements
are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this prospectus
and are subject to a number of risks, uncertainties and assumptions described in “Risk Factors” and elsewhere in this
prospectus. Because forward-looking statements are inherently subject to risks